ExpreS2ion Biotech Holding AB (publ) (STO:EXPRS2)

Sweden flag Sweden · Delayed Price · Currency is SEK
5.87
-0.07 (-1.18%)
At close: Mar 6, 2026
-77.93%
Market Cap 20.72M
Revenue (ttm) 10.85M
Net Income (ttm) -45.17M
Shares Out 3.53M
EPS (ttm) -17.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 33,119
Average Volume 22,631
Open 5.90
Previous Close 5.94
Day's Range 5.13 - 6.00
52-Week Range 5.13 - 34.20
Beta 2.37
RSI 17.54
Earnings Date Feb 19, 2026

About STO:EXPRS2

ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company’s lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalovirus vaccine program to treat infectious diseases, as well as vaccines for Nipah virus, Malaria, and influenza. In addition, the company offers a huma... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 20
Stock Exchange Nasdaq Stockholm
Ticker Symbol EXPRS2
Full Company Profile

Financial Performance

In 2024, STO:EXPRS2's revenue was 7.83 million, a decrease of -11.07% compared to the previous year's 8.80 million. Losses were -36.04 million, -60.57% less than in 2023.

Financial Statements

News

There is no news available yet.